Halopropane
From Wikipedia, the free encyclopedia
 |
|
| Systematic (IUPAC) name | |
|---|---|
|
3-Bromo-1,1,2,2-tetrafluoropropane
|
|
| Clinical data | |
| Trade names | Tebron |
| Identifiers | |
| CAS Number | 679-84-5 |
| ATC code | None |
| PubChem | CID 69623 |
| ChemSpider | 62826 |
| Chemical data | |
| Formula | C3H3BrF4 |
| Molar mass | 194.954 g/mol |
| 3D model (Jmol) | Interactive image |
|
|
|
|
Halopropane (synonym FHD-3, trade name Tebron) is a halocarbon drug which was investigated as an inhalational anesthetic but was never marketed.[1] Its clinical development was terminated due to a high incidence of cardiac arrhythmias in patients, similarly to the cases of teflurane and norflurane.[2][3][4]
See also[edit]
References[edit]
- ^ Nigel R. Webster; Helen F. Galley (22 August 2013). Landmark Papers in Anaesthesia. OUP Oxford. pp. 70–. ISBN 978-0-19-163319-5.
- ^ Acta anaesthesiologica Belgica. Acta Medica Belgica. 1974.
- ^ Sanford L. Klein (1993). A glossary of anesthesia and related terminology. Springer-Verlag. ISBN 978-0-387-97831-4.
- ^ Earl J. Catcott; J. F. Smithcors (1973). Progress in canine practice. American Veterinary Publications.
 |
This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it. |
